XTX Topco Ltd Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

XTX Topco Ltd bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 14,459 shares of the biopharmaceutical company's stock, valued at approximately $691,000.

Other large investors have also made changes to their positions in the company. Stifel Financial Corp lifted its holdings in Halozyme Therapeutics by 126.3% in the 3rd quarter. Stifel Financial Corp now owns 17,121 shares of the biopharmaceutical company's stock valued at $980,000 after purchasing an additional 9,555 shares in the last quarter. MML Investors Services LLC lifted its stake in shares of Halozyme Therapeutics by 80.7% in the third quarter. MML Investors Services LLC now owns 9,779 shares of the biopharmaceutical company's stock worth $560,000 after buying an additional 4,366 shares in the last quarter. M&T Bank Corp boosted its position in Halozyme Therapeutics by 0.5% during the third quarter. M&T Bank Corp now owns 111,239 shares of the biopharmaceutical company's stock worth $6,367,000 after acquiring an additional 561 shares during the last quarter. Virtu Financial LLC acquired a new position in Halozyme Therapeutics during the third quarter worth about $434,000. Finally, Sanctuary Advisors LLC boosted its position in Halozyme Therapeutics by 80.4% during the third quarter. Sanctuary Advisors LLC now owns 37,039 shares of the biopharmaceutical company's stock worth $2,120,000 after acquiring an additional 16,511 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Down 0.6 %

Shares of Halozyme Therapeutics stock traded down $0.37 on Wednesday, reaching $57.84. The company had a trading volume of 422,258 shares, compared to its average volume of 1,424,106. The firm's 50 day moving average price is $60.43 and its two-hundred day moving average price is $54.99. The firm has a market cap of $7.15 billion, a PE ratio of 16.86, a PEG ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 52-week low of $37.97 and a 52-week high of $66.00. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now owns 38,611 shares of the company's stock, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,200 shares of company stock valued at $1,286,568 in the last ninety days. Company insiders own 2.90% of the company's stock.

Analyst Ratings Changes

HALO has been the topic of a number of recent research reports. HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Wells Fargo & Company reduced their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Piper Sandler lifted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. Benchmark reaffirmed a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research note on Monday. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $62.89.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.